Project Grant R01HL182828
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $406K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
College Station, TX, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The University of North Texas Health Science Center at Fort Worth $426,550 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a bioengineering modular gene delivery system for lung-targeted transgene expression. The project addresses systemic gene therapy for monogenic lung diseases including cystic fibrosis, alpha-1-antitrypsin deficiency, and pulmonary arterial hypertension. The recipient...
- The National Institutes of Health National Heart Lung and Blood Institute awarded $404,424 to Texas A&M Engineering Experiment Station on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an extracellular matrix–based lymphatic patch with valved pre-collectors that restores lymphatic function and supports unidirectional lymph flow. The project addresses a gap in current regenerative approaches that promote lymphangiogenesis but fail to engineer larger...
- The National Heart, Lung, and Blood Institute awarded Carnegie Mellon University $249,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect lung spatial-biological niches in early fibrogenesis. The research project aims to spatially profile and recapitulate disease-specific microenvironments that drive early fibrogenesis in interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis. The work addresses a clinical need to elucidate...
- The National Heart Lung and Blood Institute awarded Northwestern University $104,928 for a Project Grant (K99HL188111) on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research targeting lipid signaling pathways in perivascular interstitial macrophages as a therapeutic strategy for pulmonary fibrosis. The investigator will use single-cell spatial transcriptomics and RNA sequencing to characterize how perivascular interstitial macrophages...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $108,950 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop nanoplatforms for co-delivery of drugs and genes to protect lung endothelium from neonatal and pediatric lung injury. The recipient will optimize nanoparticle formulations for stability, safety, and endothelial targeting in neonatal lungs, characterizing physicochemical properties that influence targeting...
- The National Heart, Lung, and Blood Institute awarded Beth Israel Deaconess Medical Center, Inc. $852,908 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to design and optimize elastin-like polypeptide (ELP) nanoparticles for pulmonary gene therapy of cystic fibrosis. The funded work develops fourth-generation ELP nanoparticles engineered to self-assemble into pH-responsive micellar nanoparticles for cytosolic delivery of mRNA, pDNA, proteins, and RNPs to...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $632,081 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop conformation-sensitive platelet-hitchhiking lipid nanoparticles for targeted delivery of mRNA and small interfering RNA to infarcted heart tissue following myocardial infarction. The project addresses therapeutic limitations in post-infarction recovery by engineering lipid nanoparticles to...
- The National Heart, Lung, and Blood Institute awarded Medluidics LLC $227,639 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a cardiopulmonary unit-on-a-chip for investigating right ventricular hypertrophy caused by pulmonary arterial hypertension and for developing targeted treatments. The recipient will develop a microfluidic device that models both the right ventricle and pulmonary artery separated by a collagen layer, enabling culture of...
- The National Heart, Lung, and Blood Institute awarded Duke University $215,504 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025, to fund research on epithelial cell-mediated fibroblast activation through CTHRC1-TGFB signaling in fibrotic lung diseases. The research investigates mechanisms of fibroblast activation in bronchiolitis obliterans and idiopathic pulmonary fibrosis. Aim 1 evaluates airway epithelial cell-fibroblast interactions contributing to...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate fibrotic signatures after regenerating and non-regenerating myocardial infarction. The funded research investigates cardiac fibrosis—the deposition of extracellular matrix components in the heart following myocardial injury. While early fibrosis can be protective after myocardial...